Drug intelligence / Profile preview

RBP-05

Development stage: Unknown
Lead developer: Indivior
Administration: Ophthalmic

Overview

RBP-05 is an early-stage drug candidate currently in the discovery phase, developed by ReBio Technologies (ReBio Pharma). The program is part of the company's research pipeline focusing on ocular therapeutics. RBP-05 utilizes ReBio's proprietary SiSu® formulation technology, which is designed to provide sustained release of active ingredients within the eye, typically via intravitreal injection. While the specific biological target, modality, and primary indication for RBP-05 have not been publicly disclosed, the company's broader portfolio emphasizes ocular oncology and other severe ophthalmic conditions.

Beyond the preview

Go deeper on RBP-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBP-05.

Explore the full profile